Protocol-based treatment for children with cancer in low income countries in Latin America a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO) - PART II

Pediatric Blood and Cancer

Volumn 48, Issue 4, 2007, Pages 486-490

  Howard, Scott C ^a   Ortiz, Roberta ^b   Baez, Luis Fulgencio ^b   Cabanas, Ricardo ^c   Barrantes, José ^d   Fu, Ligia ^e   Peña, Armando ^e   Samudio, Angélica ^f   Vizcaino, Martha ^g   Rodríguez Galindo, Carlos ^a   Barr, Ronald D ^h   Conter, Valentino ⁱ   Biondi, Andrea ⁱ   Masera, Giuseppe ⁱ  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Ministerio de Salud de Nicaragua   (Nicaragua)

^c Hospital Pediátrico Juan M Marquez   (Cuba)

^d HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

^e Hospital Escuela Materno Infantil   (Honduras)

^f HOSPITAL DE CLÍNICAS   (Paraguay)

^g Instituto Nacional de Cancerología   (Colombia)

^h MCMASTER CHILDREN S HOSPITAL   (Canada)

ⁱ UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Developing countries; General; Hematology Oncology; Latin America; Low income countries; MISPHO

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RETINOIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLEEDING; CANCER INCIDENCE; CENTRAL AMERICA; CHILDHOOD CANCER; CLINICAL PROTOCOL; CONFERENCE PAPER; HEALTH PROGRAM; HEPATOBLASTOMA; HISTIOCYTOSIS; HODGKIN DISEASE; HUMAN; LOWEST INCOME GROUP; NEPHROBLASTOMA; OPTIMAL DRUG DOSE; OSTEOSARCOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; RETINOBLASTOMA; RHABDOMYOSARCOMA; SINGLE DRUG DOSE; SOUTH AMERICA;

EID: 33847361878     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20989     Document Type: Conference Paper

References (37)

1. Wilimas JA, Ribeiro RC. Pediatric hematology-oncology outreach for developing countries. Hematol Oncol Clin North Am 2001;15: 775-787.
2. Barr RD, Ribeiro RC, Agarwal BR, et al. Pediatric oncology in countries with limited resources. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadephia: Lippincott, Williams and Wilkins, 2006:1604-1616.
3. Pedrosa F, Bonilla M, Liu A, et al. Effect of malnutrition at the time of diagnosis on the survival of children treated for cancer in El Salvador and Northern Brazil. J Pediatr Hematol Oncol 2000;22: 502-505.
4. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004;291:2471-2475.
5. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet 2003; 362:706-708.
6. Patte C, Michon J, Frappaz D, et al. Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: Experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 1994;7: 339-348.
7. Lemerle J. Management of cancer in children in Africa. Arch Pediatr 2003;10:247s-249s.
8. Acquatella G, Insausti CL, Garcia R, et al. Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol. Pediatr Blood Cancer 2004;43:580-586.
9. Bonilla M, Moreno N, Marina N, et al. Acute lymphoblastic leukemia in a developing country: Preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol 2000;22:495-501.
10. Eden T. Translation of cure for acute lymphoblastic leukaemia to all children. Br J Haematol 2002;118:945-951.
11. Hesseling P, Broadhead R, Mansvelt E, et al. The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer 2005;44:245-250.
12. Masera G, Lanfranco P, Sala A. The Monza's International School of Pediatric Hematology-Oncology (MISPHO) for countries with limited resources: A three year experience. Med Pediatr Oncol 1998;32:219.
13. Masera G, Baez F, Biondi A, et al. North-South twinning in paediatric haemato-oncology: The La Mascota programme, Nicaragua. Lancet 1998;352:1923-1926.
14. Darbari A, Sabin KM, Shapiro CN, et al. Epidemiology of primary hepatic malignancies in US children. Hepatology 2003;38:560-566.
15. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 2004;40:411-421.
16. Naafs-Wilstra M, Barr R, Greenberg C, et al. Pediatric oncology in developing countries: Development of an alliance of stakeholders. Med Pediatr Oncol 2001;36:305-309.
17. Neville HL, Ritchey ML. Wilms' tumor. Overview of National Wilms' Tumor Study Group results. Urol Clin North Am 2000;27: 435-442.
18. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001;138: 728-734.
19. Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 2000;212: 139-144.
20. Baker KS, Anderson JR, Link MP, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: Results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000;18:2427-2434.
21. Carli M, Pastore G, Perilongo G, et al. Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J Clin Oncol 1988;6:654-658.
22. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-630.
23. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: Results of the St. Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001;19: 171-182.
24. Baez F, Ocampo E, Conter V, et al. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 1997;8:247-250.
25. Sripada PV, Tenali SG, Vasudevan M, et al. Hybrid (COPP/ABV) therapy in childhood Hodgkin's disease: A study of 53 cases during 1989-1993 at the Cancer Institute, Madras. Pediatr Hematol Oncol 1995;12:333-341.
26. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
27. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. AML-BFM Study Group. Leukemia 2001;15:348-354.
28. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22:4384-4393.
29. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18: 72-77.
30. Dondey JC, Staffieri S, McKenzie J, et al. Retinoblastoma in Victoria, 1976-2000: Changing management trends and outcomes. Clin Experiment Ophthalmol 2004;32:354-359.
31. Gunduz K, Gunalp I, Yalcindag N, et al. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology 2004;111:1917-1924.
32. Jubran RF, Erdreich-Epstein A, Butturini A, et al. Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience. J Pediatr Hematol Oncol 2004;26:31-34.
33. Rodrigues KE, Latorre MR, de Camargo B. Delayed diagnosis in retinoblastoma. J Pediatr (Rio J) 2004;80:511-516.
34. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
35. Muwakkit SA, Razzouk BI, Shabb NS, et al. Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: A single institution's experience. J Pediatr Hematol Oncol 2004;26:749-753.
36. Klumb CE, Schramm MT, De Resende LM, et al. Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: The experience of a single center in Brazil. J Pediatr Hematol Oncol 2004;26:462-468.
37. Masera G, Baez LF, Malta CA, et al. Pediatric oncology in developing countries: A cooperative program in Nicaragua. Ann Oncol 1993;4:37-40.